The crosslinking controversy
I have just published a paper about in vivo corneal collagen cross-linking (CXL), and I believe it is certain to trigger some controversy. It is not my intention to be a heretic, but I truly believe that we should re-examine the in vivo benefits of the CXL procedure for keraoconus management. This illustration depicts the main lines of my argument. It gives the reader an insight into my standpoint as an avid evidence-based physician, and the reasons for my skepticism about the procedure.